Literature DB >> 22389452

Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens.

Christoph Willmes1, Christian Adam, Miriam Alb, Lena Völkert, Roland Houben, Jürgen C Becker, David Schrama.   

Abstract

Merkel cell carcinoma (MCC) is a rare and highly aggressive skin cancer associated with the Merkel cell polyomavirus (MCV). As MCC cell lines show oncogene addiction to the MCV T antigens, pharmacologic interference of the large T antigen (LTA) may represent an effective therapeutic approach for this deadly cancer. In this study, we investigated the effects of IFNs on MCC cell lines, especially on MCV-positive (MCV(+)) lines. Type I IFNs (i.e., Multiferon, a mix of different IFN-α subtypes, and IFN-β) strongly inhibited the cellular viability. Cell-cycle analysis showed increased sub-G fractions for these cells upon IFN treatment indicating apoptotic cell death; these effects were less pronounced for IFN-γ. Notably, this inhibitory effect of type I IFNs on MCV(+) MCC cell lines was associated with a reduced expression of the MCV LTA as well as an increased expression of promyelocytic leukemia (PML) protein, which is known to interfere with the function of the LTA. In addition, the intratumoral application of Multiferon resulted in a regression of MCV(+) but not MCV(-) MCCs in vivo. Together, our findings show that type I IFNs have a strong antitumor effect, which is at least in part explained by modulation of the virally encoded LTA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389452     DOI: 10.1158/0008-5472.CAN-11-2651

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Authors:  Natalie J Miller; Shailender Bhatia; Upendra Parvathaneni; Jayasri G Iyer; Paul Nghiem
Journal:  Curr Treat Options Oncol       Date:  2013-06

2.  Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.

Authors:  Kelly G Paulson; Andrew Tegeder; Christoph Willmes; Jayasri G Iyer; Olga K Afanasiev; David Schrama; Shinichi Koba; Renee Thibodeau; Kotaro Nagase; William T Simonson; Aaron Seo; David M Koelle; Margaret Madeleine; Shailender Bhatia; Hideki Nakajima; Shigetoshi Sano; James S Hardwick; Mary L Disis; Michele A Cleary; Jürgen C Becker; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

3.  Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma.

Authors:  Kaiji Fan; Cathrin Ritter; Paul Nghiem; Astrid Blom; Monique E Verhaegen; Andrzej Dlugosz; Niels Ødum; Anders Woetmann; Richard W Tothill; Rodney J Hicks; Michael Sand; David Schrama; Dirk Schadendorf; Selma Ugurel; Jürgen C Becker
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

4.  Interaction between Merkel cell carcinoma and the immune system: Pathogenetic and therapeutic implications.

Authors:  Irene Zanetti; Ilaria Coati; Mauro Alaibac
Journal:  Mol Clin Oncol       Date:  2017-09-01

Review 5.  Large T and small T antigens of Merkel cell polyomavirus.

Authors:  Justin A Wendzicki; Patrick S Moore; Yuan Chang
Journal:  Curr Opin Virol       Date:  2015-02-11       Impact factor: 7.090

Review 6.  Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Authors:  Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama
Journal:  Cancer Immunol Immunother       Date:  2017-11-30       Impact factor: 6.968

Review 7.  MCV and Merkel cell carcinoma: a molecular success story.

Authors:  Reety Arora; Yuan Chang; Patrick S Moore
Journal:  Curr Opin Virol       Date:  2012-06-17       Impact factor: 7.090

8.  Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma.

Authors:  R U Wahl; T Braunschweig; A Ghassemi; A Rübben
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

Review 9.  Merkel cell carcinoma.

Authors:  Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem
Journal:  Nat Rev Dis Primers       Date:  2017-10-26       Impact factor: 52.329

Review 10.  Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.